Dr. Rabb grew up in Montreal where he attended medical school at McGill University in an accelerated 5 year program with an entrance scholarship. After internship and residency in Internal Medicine at the UCLA School of Medicine, Harbor-UCLA Medical Center, he completed a clinical nephrology fellowship at the Massachusetts General Hospital and Harvard Medical School. This was followed in the same institutions by basic research training in leukocyte biology/immunology. Dr. Rabb is currently Professor and Vice Chairman (Research) in the Department of Medicine, and Medical Director of the Johns Hopkins Kidney Transplant Program.  He is a member of the American Society of Clinical Investigation, a permanent member on NIH study section, and past Chair of Scientific Studies for the American Society of Transplantation.

Clinical interest: kidney transplantation, acute renal failure

Research interests: kidney ischemic injury, lymphocytes, organ cross talk, biomarker discovery

Selected Publications

1. Rabb H, Sharma CP, Michishita M, Brown D, Arnaout MA. Regulation of complement receptor type 3 (CD11b/CD18): function and internalization by the cytoplasmic tail of its ß-subunit (CD18).  J Immunology 150:4019-4030, 1993
2. Rabb H, Mendiola CC, Dietz J, Saba SR, Issekutz TB, Abanilla F, Bonventre J, Ramirez G. Role of CD11a & CD11b in ischemic acute renal failure in rats. Am J Physiol Renal 267:F1052-1058, 1994
3. Rabb H, Martin JG. An emerging paradigm shift on the role of leukocyte adhesion molecules in inflammation. J Clin Invest 100:2937-8,1999
4. Kramer A, Postler G, Salhab K, Mendez C, Carey L, Rabb H. Renal ischemia/reperfusion leads to macrophage-mediated increase in pulmonary vascular permeability. Kidney Int 55:2362-7, 1999
5. Rabb H, Daniels F, O’Donnel M, Haq M, Saba S, Keane W, Tang W. Pathophysiologic role of T cells in renal ischemia reperfusion injury in mice. Am J Physiol Renal 279:F525-531, 2000
6. Nemoto T, Yokota N, Keane W, Rabb H. Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. Kidney Int 59:246-251, 2001
7. Burne M, Daniels F, Elgandour A, Muyeddi S, Colvin R, O’Donnell M, Rabb H. Identification of the CD4+ T cell as a major modulator of renal ischemia reperfusion injury. J Clin Invest 108:1283-90, 2001
8. Burne-Taney M, Ascon D, Yokota N, Racusen L, Baldwin W, Rabb H. B cell deficiency confers protection from renal ischemia reperfusion injury. J Immunol 171:3210-5, 2003
9. Craem J, Brady H, Rabb H. Cell-matrix and cell-cell interactions in the kidney. Ed. Brenner BM: Brenner & Rector’s The Kidney, Saunders. 2004
10. Rabb H. Paracrine and differentiation mechanism underlying stem cell therapy for the damaged kidney. Am J Physiol Renal 289:F29-30, 2003